• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Virpax Pharmaceuticals Inc.

    7/12/24 4:00:33 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRPX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001708331
    Virpax Pharmaceuticals Inc.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Virpax Pharmaceuticals, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Virpax Pharmaceuticals, Inc.
    Street Address 1 Street Address 2
    1055 WESTLAKES DRIVE, SUITE 300
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    BERWYN PENNSYLVANIA 19312 (610) 727-4597

    3. Related Persons

    Last Name First Name Middle Name
    Bruce Gerald
    Street Address 1 Street Address 2
    1055 Westlakes Drive, Suite 300
    City State/Province/Country ZIP/PostalCode
    Berwyn PENNSYLVANIA 19312
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Shah Vinay
    Street Address 1 Street Address 2
    1055 Westlakes Drive, Suite 300
    City State/Province/Country ZIP/PostalCode
    Berwyn PENNSYLVANIA 19312
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Floyd Eric
    Street Address 1 Street Address 2
    1055 Westlakes Drive, Suite 300
    City State/Province/Country ZIP/PostalCode
    Berwyn PENNSYLVANIA 19312
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Singh Vanila M.
    Street Address 1 Street Address 2
    1055 Westlakes Drive, Suite 300
    City State/Province/Country ZIP/PostalCode
    Berwyn PENNSYLVANIA 19312
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Mathias Sheila
    Street Address 1 Street Address 2
    1055 Westlakes Drive, Suite 300
    City State/Province/Country ZIP/PostalCode
    Berwyn PENNSYLVANIA 19312
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Herman Gary
    Street Address 1 Street Address 2
    1055 Westlakes Drive, Suite 300
    City State/Province/Country ZIP/PostalCode
    Berwyn PENNSYLVANIA 19312
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Su Judy
    Street Address 1 Street Address 2
    1055 Westlakes Drive, Suite 300
    City State/Province/Country ZIP/PostalCode
    Berwyn PENNSYLVANIA 19312
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Field Katharyn
    Street Address 1 Street Address 2
    1055 Westlakes Drive, Suite 300
    City State/Province/Country ZIP/PostalCode
    Berwyn PENNSYLVANIA 19312
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Dhaliwal Jatinder
    Street Address 1 Street Address 2
    1055 Westlakes Drive, Suite 300
    City State/Province/Country ZIP/PostalCode
    Berwyn PENNSYLVANIA 19312
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
    X Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-07-05    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

       Equity    Pooled Investment Fund Interests
    X Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $2,500,000 USD
    or    Indefinite
    Total Amount Sold $2,500,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Virpax Pharmaceuticals, Inc. /s/ Gerald Bruce Gerald Bruce Chief Executive Officer 2024-07-12

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $VRPX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VRPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VRPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Panis Jaydriane

    3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

    1/8/25 4:11:17 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chaudhry Usama

    3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

    1/6/25 4:05:29 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Randhawa Esha

    3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

    12/4/24 8:30:14 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Virpax Pharmaceuticals Announces Reverse Stock Split

    Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company") a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split ("reverse split") of its common stock, par value $0.0001 per share ("Common Stock"), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "VRPX" and will begin trading on a split-adjusted basis when the Nasdaq opens on March 21, 2025 ("Effective

    3/19/25 8:00:00 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

    Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding ("DRF") study. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The Company continues to work towards its Investigational New Drug (IND) application and this was another important step towards that milestone. The DRF study was conducted to evaluate the tolerance of Pr

    3/18/25 4:01:00 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

    Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look to explore delivery of vaccines via intranasal delivery similar to the FluMist which is used for patients with a fear of needles. The current vaccines in the market use lipid delivery technology to deliver mRNA to induce an immune

    3/7/25 8:00:00 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRPX
    SEC Filings

    View All

    SEC Form 25-NSE filed by Virpax Pharmaceuticals Inc.

    25-NSE - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

    7/21/25 2:57:48 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

    8-K/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

    4/3/25 5:00:46 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

    8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

    4/3/25 11:00:41 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRPX
    Financials

    Live finance-specific insights

    View All

    Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments

    Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments. "We recently reported results for a Probudur™ Maximum Tolerated Dose Study, as we continue to make steady progress in anticipation of filing our IND. The results of this study, as expected, confirmed our belief that a single injection of Probudur was well-tolerated. Our studies to date continue to reaffirm our belief that Probu

    5/13/24 4:10:00 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Pharmaceuticals Reports 2023 Year-End Results

    Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments. "We are off to a strong start in 2024 and are pleased to have regained compliance with Nasdaq. Additionally, we have executed a settlement agreement with the Plaintiffs, and can now focus on developing our non-addictive product candidates for pain management," commented Gerald W. Bruce, Chief Executive Officer of Virpax.

    3/26/24 7:30:00 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

    Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended September 30, 2023, and other recent developments. "We recently announced results from two preclinical studies for Probudur™, our lead product candidate for post operative pain, that demonstrated significantly longer efficacy in animal models than the product currently on the market today. With these solid results, we believe we are on track to file our Investigational New

    11/15/23 4:15:00 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRPX
    Leadership Updates

    Live Leadership Updates

    View All

    Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

    GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (N

    11/5/24 8:30:00 AM ET
    $ADIL
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Pharmaceuticals Announces Leadership Transition

    Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that due to ongoing litigation it has accepted the resignation of Anthony P. Mack as CEO and Chairman effective immediately. The Board has appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman. Mr. Bruce has served as the Company's Executive Vice President of Commercial Operations since August 2017, as a member of the Company's Board since July 2021 and as the President and CEO of the Company's wholly owned su

    11/17/23 7:00:00 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors

    Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has appointed Barbara A. Ruskin, Ph.D, J.D. to its Board of Directors, increasing the size of the Board to nine members. Dr. Ruskin, who received her Ph.D. in Biochemistry & Molecular Biology from Harvard University, is an experienced attorney specializing in life sciences and intellectual property. Most recently she serves as the Chief Intellectual Property and Innovation Officer for Silence Therapeutics,

    3/28/23 8:58:00 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Virpax Pharmaceuticals Inc.

    SC 13G - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

    5/23/24 4:06:37 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Virpax Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

    1/2/24 10:11:28 AM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Virpax Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

    2/14/23 4:05:43 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care